StockData
DataMeds AI, Inc. logo

DataMeds AI, Inc. (MEDS) shareholders

MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.64−0.00 (-0.28%)

Close on Nov 17, 2026Market cap $1.96MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
1.7%
0M of 3M shares
Institutional holders
10
10 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Hyperscale Data, Inc.501,2049.99%13G (passive)May 27, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MEDSValueChange% of portfolio
Jane Street Group, LLC20,5320.67%$63.65KNew0.00%
Geode Capital Management, LLC12,4670.41%$38.65KNew0.00%
Vanguard Capital Management LLC11,0850.36%$34.36KNew0.00%
Vanguard Fiduciary Trust Co6,1910.20%$19.19KNew0.00%
Barclays PLC7230.02%$2.24KNew0.00%
Tower Research Capital LLC (TRC)6780.02%$2.10KNew0.00%
Fortitude Family Office, LLC1180.00%$366New0.00%
Integrated Wealth Concepts LLC250.00%$78New0.00%
Global Retirement Partners, LLC20.00%$6New0.00%
Danske Bank A/S10.00%$3New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026100M1.7%10 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

6 funds held MEDS in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MEDSValue% of fundAs of
Fidelity Extended Market Index Fund9,3850.31%$32.10K0.00%May 31, 2026
Vanguard Extended Market Index Fund9,0590.30%$28.08K0.00%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,0260.07%$6.28K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund1,5070.05%$5.15K0.00%May 31, 2026
Fidelity Total Market Index Fund9470.03%$3.24K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund6070.02%$2.08K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Prashant PatelChief Executive Officer, Director9,354,365305.51%Jun 25, 2026
Srinivas KallaChief Information Officer293,3339.58%Apr 24, 2025
Mark DiSienaChief Financial Officer––Apr 23, 2025
Brian NortonChief Executive Officer11,524,308376.38%Mar 25, 2025
Nikul PanchalChief Pharmacy Officer375,76112.27%Mar 25, 2025
Shafaat PiraniChief Clinical Officer102,0803.33%Mar 25, 2025
Surendra K. AjjarapuDirector15,445,447504.44%Jun 25, 2026
Gary L. HermanDirector––Apr 10, 2026
Eric Michael SherbDirector––Apr 9, 2026
Marlene VelezDirector––Apr 2, 2026
Howard A. DossDirector––Oct 24, 2025
Donald G. FellDirector––Oct 21, 2025
Steven Dale LeeDirector––Oct 14, 2025
Michael L. PetersonDirector200,0006.53%Jul 8, 2025
Donald William AndersonDirector244,7207.99%Mar 25, 2025
Rebecca M. ShanahanDirector244,7207.99%Mar 25, 2025
Sajid SyedDirector244,7207.99%Mar 25, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Prashant Patel
Chief Executive Officer, Director
Jun 22, 2026Option exercise+100,000$0.01$1.00K282,365
Surendra K. Ajjarapu
Director
Jun 22, 2026Option exercise+100,000$0.01$1.00K257,645
Surendra K. Ajjarapu
Director
Mar 31, 2026Award+5,000,000$0.20$1.00M7,882,247
Prashant Patel
Chief Executive Officer, Director
Mar 31, 2026Award+5,000,000$0.20$1.00M9,118,247
Surendra K. Ajjarapu
Director
Mar 31, 2026Award+5,000,000$0.20$1.00M7,882,247
Prashant Patel
Chief Executive Officer, Director
Mar 31, 2026Award+5,000,000$0.20$1.00M9,118,247
Michael L. Peterson
Director
Jul 2, 2025Award−200,000$0.90$180.00K200,000
Surendra K. Ajjarapu
Director
Mar 21, 2025Award+600,000––4,463,200
Surendra K. Ajjarapu
Director
Mar 21, 2025Award+600,000––3,100,000
Surendra K. Ajjarapu
Director
Mar 21, 2025Award+2,882,247––1,822,247
Prashant Patel
Chief Strategy Officer, Director
Mar 21, 2025Award+1,882,247––4,118,247
Prashant Patel
Chief Strategy Officer, Director
Mar 21, 2025Award+1,500,000––1,500,000
Prashant Patel
Chief Strategy Officer, Director
Mar 21, 2025Award+700,000––700,000
Shafaat Pirani
Chief Clinical Officer
Mar 21, 2025Award+35,000––102,080
Donald William Anderson
Director
Mar 21, 2025Award+200,000––244,720
Rebecca M. Shanahan
Director
Mar 21, 2025Award+200,000––244,720
Brian Norton
Chief Executive Officer
Mar 21, 2025Award+9,000,000––9,044,720
Sajid Syed
Director
Mar 21, 2025Award+200,000––244,720
Nikul Panchal
Chief Pharmacy Officer
Mar 21, 2025Award+90,000––90,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
12.13%
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
-22.0%
From 0M shares
Short volume, 20 days
55.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of DataMeds AI's stock actually held short. Settlement fails (shares not delivered on time) peaked at 281,963 shares on Sep 16, 2026 over the last 90 days.

See a number that looks wrong?